sglt1/2 in 2

SGLT1/2-IN-2 is a chemical compound with robust dual inhibitory properties, exhibiting potent activities against SGLT1 (IC50 = 96 nM) and SGLT2 (IC50 = 1.3 nM).

SGLT1/2-IN-8 (compound 8) is a potent and orally active dual inhibitor of SGLT1/2, exhibiting IC50 values of 4 nM and 1 nM, respectively. It shows antihyperglycemic properties, making it suitable for related research.

SGLT1/2-IN-1 is a dual inhibitor of SGLT1 and SGLT2.

Ipragliflozin (ASP1941) is under investigation in Type 2 Diabetes and Diabetes Mellitus, Type 2.

Bexagliflozin (also known as EGT1442) is a potent and selective SGLT2 inhibitor that effectively reduces blood glucose and HbA(1c) levels in db/db mice while increasing the survival time of stroke-prone rats. The IC(50) values of EGT1442 for human SGLT1 and SGLT2 are 5.6 μM and 2 nM, respectively. In studies involving normal rats and dogs, EGT1442 induces saturated urinary glucose excretion with ED(50) values of 0.38 mg/kg and 0.09 mg/kg, respectively. Additionally, EGT1442 exhibits favorable properties in both in vivo and in vitro studies, indicating its potential positive impact on the management of type 2 diabetes.

Trilobatin (Standard) is a reference standard for research and analysis in studies involving Trilobatin. Trilobatin (P-Phlorizin) has anti-oxidant effect, can increase superoxide dismutase (SOD) activity.Trilobatin has anti-inflammatory effect, it potentially inhibits the lipopolysaccharide (LPS)-induced inflammatory response by suppressing the NF-κB signaling pathway.Trilobatin shows a strong inhibitory activity against α-glucosidase and a moderate inhibitory activity against α-amylase for management of postprandial hyperglycemia with less side effect.